<DOC>
	<DOCNO>NCT02414880</DOCNO>
	<brief_summary>Liver cirrhosis progressive disease characterize loss functional hepatocytes substantially affect drug pharmacokinetics . Rocuronium onset time longer recovery time prolonged cirrhotic patient normal liver function . This randomize control study design compare pharmacodynamic profile sugammadex neostigmine use antagonism moderate degree rocuronium-induced neuromuscular block cirrhotic patient undergo liver resection patient preoperative normal liver function undergo liver resection .</brief_summary>
	<brief_title>Sugammadex Versus Neostigmine Patients With Liver Cirrhosis Undergoing Liver Resection</brief_title>
	<detailed_description>Liver resection lengthy operation major effect patient hemodynamics perioperative liver function . These effect obvious patient liver cirrhosis . Liver cirrhosis progressive disease characterize loss functional hepatocytes substantially affect drug pharmacokinetics . Rocuronium intermediate act steroidal non-depolarizing neuromuscular blocker mostly metabolize liver . Its onset time longer cirrhotic patient normal liver function . This explained increase volume initially distribute . Although elimination kinetics unchanged patient cirrhosis , Rocuronium recovery time prolonged cirrhotic patient . To speed process antagonism residual neuromuscular blockade , inhibitor acetyl cholinesterase Neostigmine usually administer evidence spontaneous recovery neuromuscular function . Too early administration Neostigmine effective may produce serious side-effects accumulation Acetylcholine organs , especially brain heart . Sugammadex , modify Î³-cyclodextrin , first selective relaxant binding agent . It form tight , stable complex 1:1 ratio Rocuronium . The inactive Sugammadex-Rocuronium complex undergo renal elimination . Sugammadex effect acetyl cholinesterase receptor system body , eliminate need anticholinergic drug . Sugammadex antagonize level neuromuscular blockade , include profound blockade induce Rocuronium . The use Sugammadex different patient population include end-stage renal failure associate consistent , complete rapid recovery neuromuscular function . It clinical relevance note presence Sugammadex , hepatic biotransformation final clearance Rocuronium via biliary excretion change completely different ( liver-independent ) renal pathway . A recent report describe successful use Sugammadex antagonize prolonged deep rocuronium-induced neuromuscular block patient normal liver function undergo liver resection . Furthermore , successful use Sugammadex antagonize Rocuronium neuromuscular block also report case series three patient liver dysfunction . To best knowledge , control randomized study evaluate use Sugammadex antagonize residual Rocuronium-induced neuromuscular blockade patient liver cirrhosis undergo open surgical liver resection . This randomize control study design compare pharmacodynamic profile Sugammadex Neostigmine use antagonism moderate degree Rocuronium-induced neuromuscular block cirrhotic patient undergo liver resection patient preoperative normal liver function undergo liver resection .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>American Society Anesthesiologists physical status ( ASA ) class I patient preoperative normal liver function test ( two group ) IIII patient liver cirrhosis ( two group ) . For two `` Liver Cirrhosis '' group : Patients liver Cirrhosis Child classification `` A '' Model EndStage Liver Disease ( MELD ) score &lt; 10 undergoing Liver resection surgery . For two `` Normal Liver '' group : Patients normal preoperative liver function undergo Liver resection surgery . Coexisting neuromuscular disease . Body mass index 35 kg/m2 . Renal impairment . Medications know affect neuromuscular transmission ( e.g . Aminoglycoside antibiotic Magnesium Sulphate ) . Bleeding tendency . Intraoperative adverse event ( e.g . massive bleeding hypothermia ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Sugammadex</keyword>
	<keyword>Neostigmine</keyword>
	<keyword>Rocuronium</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Liver resection</keyword>
	<keyword>Neuromuscular</keyword>
</DOC>